Specialty pharmaceutical company in the US Sagent Pharmaceuticals has announced the approval of Zoledronic Acid Injection 4mg per 100l in a ready-to-use premix IV bag.
Zoledronic Acid Injection is the generic form of the bisphosphonate Zometa.
According to the company, as with all products in its portfolio, Zoledronic features the company’s PreventIV Measures packaging and labeling, designed to help reduce medication errors.
Sagent chief executive officer and chairman of the board Jeffrey Yordon said the company anticipates its premix bag presentation will complement the vial product which was launched on 5 March.
"Sagent is pleased to announce the approval of Zoledronic Acid Injection 4mg in the enhanced packaging option of a ready-to-use premix bag," Yordon added.
The package insert contains the indications, complete side effect profile and prescribing information.